Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin's Effect on CD34+ Stem Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 30-70 years~* Diagnosis of type 2 diabetes within the previous 15 years using criteria of the American Diabetes Association~* Currently being treated with 1-2 grams/day of metformin, or insulin or both stably~* Hemoglobin A1c (HbA1C) between 6.5% to 10.0% (both inclusive)~* Body Mass Index (BMI) between 25 and 39.9 kg/m2 (both inclusive)~* Chronic Kidney disease (CKD) Stages 1-3, Creatinine clearance (CrCl) less than 90 and more than 29~Exclusion Criteria:~* Type 1 diabetes~* History of Diabetic Ketoacidosis (DKA) or hyperosmolar nonketotic coma~* Hemoglobinopathies with low hematocrit (Below 28 Units)~* History of pancreatitis~* History of cancer within the past 5 years (except basal cell carcinoma)~* Previous cardiovascular or cerebrovascular event within 6 months of screening or active or clinically significant coronary and/or Peripheral Vascular Disease (PVD)~* Statin use started in the last 3 month~* Current use of oral or injectable anti-diabetic medication other than Metformin and insulin~* Consistent use of steroids within the last 3 months~* Any active wounds, or surgery within the past 3 months~* Inflammatory disease, or the chronic use of anti-inflammatory drugs within the past 3 months~* Untreated hyper/hypothyroidism~* Contraindications to moderate exercise~* Implanted devices that might interact with the tanita scale~* Pre-existing liver disease and/or Alanine aminotransferase (ALT) and Aspartate Aminotransferase (AST) \> 2.5 times Under the Normal Limits (UNL)~* Untreated Systolic blood pressure \> 140 mmHg or diastolic blood pressure\> 90 mmHg~* Serum creatinine levels ≥ 2.0~* CKD Stages 4 and 5 (estimated CrCl \<30 mL/min)~* Triglycerides \> 450 mg/dL~* Known allergies or hypersensitivities to Linagliptin or Dipeptidyl peptidase-4 (DDP-4) inhibitors~* Treatment with cytochrome p450 (CYP 3A4) inhibitors~* Women of child bearing age who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study~* Prisoners or subjects that are involuntarily incarcerated~* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness~* Additionally, patients who are active smokers, patients who are pregnant, nursing women, and post-menopausal women who are on hormone replacement therapy will be excluded.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo 1 pill daily for 12 weeks
- Linagliptin (Type: ACTIVE_COMPARATOR): Linagliptin 5mg once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).